Detection of hepatitis B virus genotypes using oligonucleotide chip among hepatitis B virus carriers in Eastern China

Table 1 Clinical and demographic data of 400 HBV-infected patients

	Gender (male/female)	Age (yr)	HBV DNA (copies/mL)	HbeAg+/HbeAg -	ALT (IU/L)
Acute infection (n = 18)	13/5	33.1 ± 9.8	1.5 × 107 (3.6 × 104 - 9.6 × 109)	14/4	317.1 ± 630.4
Asymptomatic carrier (n = 44)	27/17	28.7 ± 10.2	4.6 × 104 (1.2 × 103 - 5.6 × 106)	14/30	15.4 ± 8.7
Chronic hepatitis (n = 251)	190/61	39.1 ± 10.1	1.4 × 106 (1.3 × 103 - 7.5 × 109)	165/86	219.6 ± 312.4
Liver cirrhosis (n = 74)	47/27	49.7 ± 16.2	2.2 × 105 (5.3 × 103 - 4.7 × 106)	33/41	49.3 ± 59.8
HCC (n = 13)	10/3	54.3 ± 15.4	5.6 × 104 (1.2 × 103 - 3.8 × 106)	7/6	192 ± 327.1

ALT: Alanine aminotransferase; HBeAg: Hepatitis B e antigen; HCC: Hepatocellular carcinoma.

Table 2 Probe sequence used for HBV genotyping

Genotype	Oligonucleotide sequence	Tm (°C)
A	5’-NH2-(T)16-AAC CCC (A/G)TC AAG GAC CAC TG-3’	56
B	5’-NH2-(T)16-CCC TGC ATT CAA AGC CAA CTC-3’	56
C	5’-NH2-(T)16-CTT CAA CCC CAA CAA GGA TCA-3’	54
D	5’-NH2-(T)16-CAA TCC CAA CAA GGA CAC CTG-3’	55
E	5’-NH2-(T)16-GAC CAC AAT CCC AAC AAA GAC C-3’	55
F	5’-NH2-(T)16-TGG CCA ATG GCA AAC AAG G-3’	54
G	5’-NH2-(T)16-CAA TCC CAA AAA GGA CCC TTG-3’	54
H	5’-NH2-(T)16-CTC TCA ACG GCG AGA AGG G-3’	54
QC probe	5’-NH2-(T)16-TGG GGT GGA GCC CTC AG-3’	59
PC probe	5’-NH2-(T)16- ATC CTC AGG CCA TGC AGT G-3’	58

Table 3 Genotype distribution of HBV in cases of different liver diseases n (%)

Diseases	Genotype
	B (n = 33)	C (n = 333)	B + C (n = 34)
Acute infection (n = 18)	2 (11.1)	13 (72.2)	3 (16.7)
Asymptomatic carrier (n = 44)	8 (18.2)a	32 (72.7)a	4 (9.1)
Chronic hepatitis (n = 251)	19 (7.6)a	211 (84.1)a	21 (8.4)
Liver cirrhosis (n = 74)	4 (5.4)a	65 (87.8)a	5 (6.7)
HCC (n = 13))	0 (0)	12 (92.3)	1 (7.7)

χ² test; genotype B vs C in different liver diseases. A significant difference was found between asymptomatic carriers and advanced liver diseases (CH and LC) (0.01 <

^aP < 0.05). HCC: Hepatocellular carcinoma.